EHRA 2023: Late-Breaking Science Video Collection

Published: 18 April 2023

  • Views:

    Views Icon 1766
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating


For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research and clinical practice. 

About the episode

EHRA 23 - We are joined onsite by Prof Carlo Pappone (IRCCS Policlinico San Donato, IT) who outlines the key findings of the BRUGADA Randomized trial.

In a randomized controlled trial, 150 patients with Brugada syndrome were enrolled in to develop an evidence-based treatment for the condition. Patients were randomized in a 2:1 fashion to receive either catheter ablation treatment with an ICD, or an ICD alone to evaluate the effectiveness of epicardial ablation in reducing rates of sudden cardiac death. 


  1. What is the reasoning behind this study?
  2. What are the unmet needs in the treatment of Brugada Syndrome?
  3. What was the study design and patient population?
  4. What are the key findings?
  5. What could be the impact of these results on clinical practice?
  6. What further research is needed?

Recorded at EHRA 2023, Barcelona.

Faculty Biographies

Carlo Pappone

Carlo Pappone

Director, Clinical Arrhythmology and Electrophysiology

Dr. Carlo Pappone is currently Director of the Department of Arrhythmology at the Hospital San Raffaele in Milan, Italy. 

He is author of more than 140 peer-reviewed papers, related to many areas of Cardiology specialty. He is member of the editorial board/consultant Reviewer of several scientific journals, like Circulation, Circulation AE, JACC, NEJM, Lancet, JAMA, Heart Rhythm, etc. His main interest is cardiac electrophysiology and catheter ablation of all types of arrhythmias including Brugada syndrome as well as electrical devicetherapy for patients with heart failure.

Dr Pappone is a member of the Arrhythmia & Electrophysiology Review editorial board.


View full profile


You must be to comment. If you are not registered, you can register here.